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Abstract: The signal transducer and activator of transcription 3 (STAT3) protein is a major
transcription factor involved in many cellular processes, such as cell growth and proliferation,
differentiation, migration, and cell death or cell apoptosis. It is activated in response to a variety
of extracellular stimuli including cytokines and growth factors. The aberrant activation of STAT3
contributes to several human diseases, particularly cancer. Consequently, STAT3-mediated signaling
continues to be extensively studied in order to identify potential targets for the development
of new and more effective clinical therapeutics. STAT3 activation can be regulated, either
positively or negatively, by different posttranslational mechanisms including serine or tyrosine
phosphorylation/dephosphorylation, acetylation, or demethylation. One of the major mechanisms
that negatively regulates STAT3 activation is dephosphorylation of the tyrosine residue essential
for its activation by protein tyrosine phosphatases (PTPs). There are seven PTPs that have been
shown to dephosphorylate STAT3 and, thereby, regulate STAT3 signaling: PTP receptor-type D
(PTPRD), PTP receptor-type T (PTPRT), PTP receptor-type K (PTPRK), Src homology region 2
(SH-2) domain-containing phosphatase 1(SHP1), SH-2 domain-containing phosphatase 2 (SHP2),
MEG2/PTP non-receptor type 9 (PTPN9), and T-cell PTP (TC-PTP)/PTP non-receptor type 2 (PTPN2).
These regulators have great potential as targets for the development of more effective therapies
against human disease, including cancer.
Keywords: STAT3; PTPRT; PTPRD; SHP1; SHP2; TC-PTP

1. Introduction
The signal transducer and activator of transcription (STAT) protein family includes intracellular
latent transcription factors that facilitate the cellular signaling initiated by stimuli from growth factors
and cytokines that is required for multiple key cellular processes. Currently, there are seven known
members of the STAT family in humans: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6.
Signal transducer and activator of transcription 3 (STAT3, encoded by the STAT3 gene) is the most
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Figure 1. Schematic of the full-length signal transducer and activator of transcription 3 (STAT3) protein
Figure 1. Schematic of the full-length signal transducer and activator of transcription 3 (STAT3)
structure. STAT3 is comprised of six conserved domains: an N-terminal domain, a coiled-coil domain,
protein structure. STAT3 is comprised of six conserved domains: an N-terminal domain, a coiled-coil
a DNA-binding domain, a linker domain, a Src homology region 2 (SH-2) domain, and a C-terminal
domain, a DNA-binding domain, a linker domain, a Src homology region 2 (SH-2) domain, and a Ctransactivation domain. The transactivation domain contains two phosphorylation (P) sites: a tyrosine
terminal transactivation domain. The transactivation domain contains two phosphorylation (P) sites:
residue (Y) at 705, which is required for STAT3 activation, and a serine residue (S) at 727. Once STAT3
a tyrosine residue (Y) at 705, which is required for STAT3 activation, and a serine residue (S) at 727.
is activated, the P(Y)–SH-2 domains interact to form a STAT3 dimer. (A) STAT3α, the full-length form
Once STAT3 is activated, the P(Y)–SH-2 domains interact to form a STAT3 dimer. (A) STAT3α, the
of STAT3; (B) STAT3β is a C-terminal truncated form of STAT3 generated by an alternative splicing.
full-length form of STAT3; (B) STAT3β is a C-terminal truncated form of STAT3 generated by an
STAT3β does not contain a serine phosphorylation site at 727.
alternative splicing. STAT3β does not contain a serine phosphorylation site at 727.
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STAT signaling, particularly in the development of a variety of human diseases, such as cancer, the
relationship between PTPs and STATs has still not been completely characterized. Here, we will review
the PTPs that have been implicated in the inactivation of STAT3, with an emphasis on PTP regulation
of STAT3 signaling in cancer.
2. Protein Tyrosine Phosphatase Receptor-Type D
PTP receptor-type D or PTPRD (PTPδ) is a member of the highly conserved family of receptor
PTPs that is encoded by the PTPRD gene. It is classified as a member of the LAR subfamily of
transmembrane PTPs, which includes LAR and PTPσ (PTPRS) [22,23]. PTPRD is a transmembrane
protein composed of an extracellular region, which possesses three Ig-like and eight fibronectin-type
III-like domains, a single transmembrane region, and two tandem intracytoplasmic catalytic domains,
referred to as D1 and D2. The extracellular region is similar in structure to cell adhesion molecules,
implying that PTPRD, and other receptor-type PTPs like it, have similar ligands and functions [23,24].
In fact, PTPRD is known to be a ligand for cell adhesion and neurite outgrowth, and different truncated
isoforms can be produced through alternative splicing, depending on the requirements of the different
tissue and developmental stages [25]. PTPRD is expressed in astrocytes and tissue, such as brain, colon,
and breast tissues [26].
Receptor-type PTPs have been shown to be inactivated in a number of human cancers, implying
that these PTPs have tumor suppressive capabilities. The PTPRD gene, specifically, is frequently
inactivated by genetic (deletion, mutation, copy number loss) or epigenetic (hypermethylation)
mechanisms in cancers, such as glioblastoma multiforme (GBM), colon cancer, breast cancer,
neuroblastoma, lung cancer, and squamous cell carcinoma (SCC) [24,26–32]. These findings indicate
that PTPRD is a major tumor suppressor, and in fact, functional studies have revealed that
PTPRD-deficiency enhanced the tumor-forming capability of immortalized human astrocytes in mouse
xenograft models [26]. Another study showed that homozygous or heterozygous deletion of Ptprd in
the absence of Cdkn2a, a gene that encodes the tumor suppressors p16Ink4 and p14/p19Arf , resulted
in increased tumorigenesis in comparison to mice with Cdkn2a deletion alone, and Ptprd-deficiency
may influence which types of tumors form [30]. PTPRD cooperates with CD44 and β-catenin/TCF
signaling to regulate cell migration and progression in colon cancer [24]. CD44 is a major cell-surface
glycoprotein, critical to cancer invasion and metastasis, which can function as a marker for cancer
stem cells, cells that can give rise to the many cell types that form tumors. Additionally, it has
been shown that the exogenous expression of PTPRD in PTPRD-deficient primary melanoma cells
significantly decreased cell growth and cell viability, and it yielded an increase in apoptosis in a
time-dependent manner; however, the expression of PTPRD containing cancer-specific mutations
reversed this effect [29].
PTPRD is capable of directly interacting with PTPRS [22], the cytoskeletal remodeling proteins
liprin-α-1 and MIM (Missing in Metastasis) [23,24], and STAT3 [26,30,33], which suggests that PTPRD
may play a functional role in cancer cell survival, adhesion, and/or migration through the signaling
mechanisms mediated by these substrates. Veeriah et al. demonstrated that PTPRD acts as a tumor
suppressor through its ability to negatively regulate STAT3-mediated signaling [26]. The exogenous
expression of PTPRD in human GBM and other cancer cell lines inhibited cell growth, which coincided
with a substantial decrease in the expression levels of phosphorylated STAT3 (Y705) and, consequently,
one of its downstream targets, suppressor of cytokine signaling 3 (SOCS3) [26]. However, the
expression of PTPRD containing cancer-specific mutations reversed the inhibitory effect on cell growth
and STAT3 phosphorylation. Immunoprecipitation assays confirmed that PTPRD directly interacts
with STAT3 [26]. Heterologous loss of Ptprd or PTPRD is sufficient to see a significant increase in STAT3
phosphorylation and an upregulation of STAT3 target genes within GBM tumors [30]. Loss-of-function
mutations in PTPRD contribute to enhanced cell growth and increased levels of phosphorylated STAT3
(Y705) in head and neck SCC cells [31]. Interestingly, head and neck SCC cells containing a PTPRD
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mutation were more susceptible to a STAT3 inhibitor, suggesting that use of this type of anti-cancer
drug could be utilized for more successful treatments of head and neck SCC patients [31].
3. Protein Tyrosine Phosphatase Receptor-Type T
PTP receptor-type T (PTPRT), alternatively known as PTPρ, is another receptor PTP that belongs
to the type IIB receptor-type (R2A) PTP subfamily, which also includes PTPRK (PTPκ), PTPRM (PTPµ),
and PTPRU (otherwise known as PCP-2). It is composed of an extracellular domain containing a MAM
(meprin/A5/PTPµ) domain and an Ig domain and four fibronectin-type III repeats, a transmembrane
domain, a juxtamembrane region, and two phosphatase domains, referred to as D1 and D2. Primarily,
D1 is responsible for the catalytic activity of PTPRT, whereas D2 is more important for regulation [34].
PTPRT is largely expressed in the brain and spinal cord. It plays a role in cell adhesion through
its extracellular domain [35–37], and it serves an important function in neurological development.
For instance, PTPRT has been shown to directly dephosphorylate E-cadherin at intercellular adheren
junctions to regulate hemophilic cell–cell adhesion in the central nervous system [38]. Also, it stimulates
synapse formation through its interaction with neuroligin and neurexin, proteins that connect and
maintain the synapse between neurons [39].
Like PTPRD, PTPRT is inactivated by mutation in many cancers, including lung cancer, gastric
cancer, and head and neck SCC, and it is most frequently mutated in colorectal cancer (CRC) [40–43].
Mutations in PTPRT consist of nonsense, insertion, and deletion mutations, with the majority
being missense mutations. Missense mutations in the catalytic domain have been implicated in
reducing its phosphatase activity, and mutations in the extracellular domain impair its function in
cell adhesion [35,42,44]. PTPRT can function as a tumor suppressor through its interaction with its
substrates, paxillin and STAT3 [40,41]. The knockout of PTPRT has resulted in increased colon tumor
formation in a mouse model, which correlates with increased paxillin phosphorylation [44]. The
activation of paxillin triggers the activation of AKT (protein kinase B), a major kinase involved in
oncogenic signaling. Zhang et al. [41] demonstrated that PTPRT negatively regulates STAT3-mediated
signaling by directly dephosphorylating STAT3 at Y705, which prohibits STAT3 nuclear translocation,
resulting in a variety of effects depending on the cancer type. Whole exome sequencing and
reverse-phase protein array analysis showed that PTPRT mutations are associated with increased
STAT3 activation in head and neck SCC, leading to increased cell survival and, therefore, may serve
as a biomarker to predict the efficacy of STAT3 inhibitors as a chemotherapeutic [43]. Many human
cancers show aberrant hypermethylation of the PTPRT promoter, which results in the decreased
expression of PTPRT mRNA [45]. Peyser et al. [45] showed that this decrease correlated with an
increase in phosphorylated STAT3 in head and neck SCC and sensitivity to STAT3 inhibition. These
findings suggest that PTPRT hypermethylation could also function as a biomarker for the efficacy of
STAT3 inhibitors against cancer. Furthermore, it has been shown that post-translational modification
of PTPRT by glycosylation reduces its activity by causing it to dimerize, which has been shown to
result in enhanced cancer cell migration via the activation of STAT3-mediated signaling [46].
4. Protein Tyrosine Phosphatase Receptor-Type K
As previously mentioned, PTPRK (encoded by PTPRK) is a R2A subfamily member with PTPRT,
and it functions in homophilic binding via its extracellular domain [47]. PTPRK is expressed in
the cytoplasm of different tissues and cell types, including the central nervous system and human
keratinocytes [48]. It has been shown to mediate neurite outgrowth via a Grb2/MEK1-dependent
signaling pathway and T-cell development [49,50]. In keratinocytes, transforming growth factor β1
(TGF-β1) inhibits cell proliferation and triggers cell migration through the upregulation of PTPRK [48].
Additionally, PTPRK was found to co-localize with β-catenin at adherens junctions, suggesting that
PTPRK plays a role in cell contact and adhesion, such as PTPRD and PTPRT [51,52]. Indeed, further
studies have demonstrated, for example, that PTPRK negatively regulated adhesion and invasion
in breast cancer cells [53]. The expression of PTPRK mRNA transcript was reduced in the primary
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tumors harvested from breast cancer patients with metastatic tumors or who had succumbed to the
disease. Furthermore, patients who expressed higher levels of PTPRK survived longer than patients
with low levels. In vitro studies confirmed that the knockdown of PTPRK increased cell proliferation,
adhesion, and invasion, suggesting it functions as a tumor suppressor in breast cancer [53]. PTPRK
has also been shown to act as a tumor suppressor in central nervous system lymphomas, CRC, and
prostate cancer [54–56]. The use of mapping arrays revealed that genetic alterations (gene deletion and
missense mutations) of PTPRK could be found in glioma biopsies, and they disrupt PTPRK activity
and post-translational regulation [57].
Some major substrates of PTPRK that have been identified are epidermal growth factor
receptor (EGFR) and STAT3. PTPRK can directly dephosphorylate EGFR during both basal- and
ligand-stimulated EGFR phosphorylation, and it can contribute to tumor suppression through its
negative regulation of EGFR signaling [58–60]. Chen et al. were the first to demonstrate that PTPRK
directly interacts with and dephosphorylates active STAT3 at Y705 [61]. Their studies revealed that the
expression of PTPRK was decreased in nasal-type natural killer T-cell lymphoma (NKTCL) human
cell lines and primary tumors, and this decrease was inversely correlated with phosphorylated STAT3
(Y705) expression; the knockdown of PTPRK further decreased the expression levels of phosphorylated
STAT3, whereas the overexpression of PTPRK reversed this effect, which resulted in increased
NKTCL cell growth and invasion [61]. Additionally, Chen et al. [61] found that decreased PTPRK
expression was a result of decreased PTPRK mRNA levels due to monoallelic deletion and promoter
hypermethylation, and these genetic alterations were associated with a poor prognosis for NKTCL
patients undergoing standard treatment.
5. Src Homology Region 2 Domain-Containing Phosphatase 1
Src homology region 2 (SH-2) domain-containing phosphatase 1, or SHP1, is a non-receptor
PTP encoded by PTPN6. SHP1 is a member of a subfamily of non-transmembrane PTPs that are
composed of two tandem N-terminal Src homolog domains (N-SH2 and D-SH2), a classic catalytic
PTP domain, and a C-terminal tail containing two sites for tyrosine phosphorylation and a nuclear
localization signal [62–64]. There are two forms of SHP1, which differ by their N-terminal amino acid
sequences: form I contains MLSRG, and form II contains MVR. The expression of these isoforms are
regulated by either promoter 1, which is found in nonhematopoietic-derived cells, or promoter 2,
which is exclusively active in hematopoietic-derived cells [65]. SHP1 is most abundantly expressed
in the nucleus of epithelial cells and the cytoplasm of hematopoietic cells, although stimulation by
cytokines can induce nuclear translocation of SHP1 in hemopoietic cells [63]. The binding of SHP1 at
its N-terminal SH-2 domain to a specific motif—the immune-receptor tyrosine-based inhibitory motif
(IVLxYxxIVL)—in receptors, scaffold adapters, or immune inhibitory receptors causes a conformational
change that actives SHP1 by exposing its active site to its substrates [63,66]. The modification of the
C-terminal tail by truncation, phospholipid binding, or tyrosine phosphorylation has been implicated
in the regulation of SHP1 phosphatase activity, and moreover, it was shown that Src kinase is one
kinase that phosphorylates SHP1 in order to allow SHP1 to more readily dephosphorylate Src-activated
substrates [67]. SHP1 is a major negative regulator of cytokine-mediated signaling pathways, such as
inflammatory protein interleukin (IL)-3 receptor signaling and epidermal growth factor (EGF) signaling,
in lymphocytes, which facilitate lymphocyte activation for cell proliferation and differentiation [66,68].
On the other hand, SHP1 has been implicated in the positive regulation of glia cell differentiation and
Ras-dependent MAPK activation [67].
The downregulation or loss of SHP1 protein expression is a characteristic of human lymphoma and
leukemia, and in fact, methylation of the PTPN6 promoter, resulting in suppressed SHP1 expression,
was found in anaplastic large cell lymphoma (ALCL), multiple myeloma, T-cell lymphoma, and
B-cell lymphoma [68–74]. STAT3 and DNA methyltransferase 1 appear to function cooperatively to
promote this epigenetic silencing in T-cell lymphoma [74]. Additionally, a recent study identified
loss-of-function point mutations within PTPN6 in diffuse large B-cell lymphoma [75]. Altered SHP1
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expression has also been noted in breast, ovarian, prostate, and pancreatic cancers [65]. The tumor
suppressive capability of SHP1 occurs through its regulation of JAK and STAT. For example, Han et
al. [68] demonstrated that overexpression of SHP1 in ALK+ ALCL cells—a distinct type of non-Hodgkin
lymphoma—which are deficient in SHP1, reversed JAK3 and STAT3 activation, which corresponded
with a decrease in STAT3 targets. It was also shown that SHP1 downregulates JAK3 via increased
proteasome degradation [68]. Research into the chemotherapeutic properties of various compounds
have revealed the importance of SHP1 regulation of JAK/STAT signaling in the efficacy of these
compounds. Guggulsterone (GS), a phytosteroid extracted from the guggul plant, can induce apoptosis
and suppress the proliferation of multiple cancer types, such as leukemia, head and neck SCC, and
melanoma. Ahn et al. demonstrated that GS induces SHP1 expression, which resulted in the inhibition
of JAK2 activation and markedly decreased STAT3 phosphorylation [76]. Dovitinib, a multi-targeted
receptor kinase inhibitor, was shown to directly and effectively induce SHP1 activity, leading to
decreased STAT3 phosphorylation, the inhibition of hepatocellular carcinoma (HCC) growth, and an
increase in apoptosis [77]. These findings further implied that the use of dovitinib in combination
with the current clinical drug, sorafenib, could help overcome chemoresistance in HCC. However, a
recent study was able to generate sorafenib derivatives that more effectively activate SHP1 activity
and, thereby, inhibit STAT3 activation and suppress cancer cell growth to combat tumorigenesis and
chemoresistance [78]. Plumbagin, a vitamin K3 analogue derived from a medicinal plant, induces
the expression of SHP1 in human multiple myeloma cells, which resulted in the inhibition of STAT3
phosphorylation via the inactivation of c-Src, JAK1, and JAK2 [79]. In epidermal keratinocytes,
SHP1 is initially activated in response to ultraviolet B (UVB) exposure and contributes to reduced
STAT3 phosphorylation in cooperation with other PTPs, Src homology region 2 domain-containing
phosphatase-2 (SHP2) and T-cell PTP (TC-PTP), implying that SHP1 is involved in an initial protective
mechanism against UVB-induced skin cancer formation [80].
It is important to note that the modulation of SHP1 expression can play a role in noncancerous
disease as well. Ruchusatsawat et al. [81] revealed that the PTPN6 promoter 2 is methylated in normal
epithelial cells and tissues to repress SHP1 expression; however, a significant increase in demethylation
was observed in psoriatic skin lesions, resulting in the expression of SHP1 isoform II. Psoriasis is
a T-cell mediated disease that involves the dysregulation of MAPK and JAK/STAT signaling [81].
Another study has shown that SHP1 deficiency in mice resulted in inflammatory skin disease due to
abnormal toll-like receptor (TLR) activation leading to increased IL-1β production in neutrophils [82].
Along with STAT3, SHP1 has been reported to regulate STAT5 and STAT6. STAT5 plays a
role in many hematopoietic malignancies. For example, SHP1 mRNA and protein levels were
found to be significantly reduced in patients with chronic myelogenous leukemia as a result of
hypermethylation of the PTPN6 promoter, and an in vitro study revealed that the overexpression of
SHP1 negatively regulated several signaling pathways, including JAK2/STAT5 signaling [83]. Another
recent study showed that phospholipase C β3 (PLC-β3) recruits SHP1 and STAT5 to its C-terminal
domain to facilitate the dephosphorylation of STAT5, which inhibits cell proliferation, survival, and
differentiation, leading to the suppression of myeloproliferative disease, lymphoma, and other tumors
in PLC-β3 knockout mice [84]. Interestingly, PLC-β3 knockout mice can spontaneously develop atopic
dermatitis-like skin lesions and severe allergen-induced dermatitis, and these symptoms required the
presence of mast cells [85]. These mast cells were sensitive to IL-3 stimulation due to the increased
STAT5 activation, which could be reversed by SHP1. STAT6 is involved in IL-4-mediated cellular
processes, and SHP1 has been shown to regulate IL-4 induction of STAT6 activation, which may
contribute to T-cell homeostasis [86–88].
6. Src Homology Region 2 Domain-Containing Phosphatase-2
SHP2 is a ubiquitously expressed, cytosolic non-receptor PTP, encoded by PTPN11. It has an
identical structure to SHP1 except that its C-terminal tail contains proline-rich domains instead of a
nuclear localization sequence (NLS). So, as with SHP1, it is auto-inhibited by the N-terminal SH-2
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domains [63]. SHP2 functions as a major regulator of the cell signaling required for cell growth,
transformation, differentiation, spreading, migration, and cytoskeleton organization [89–91]. It enhances
signal transduction through its interactions with different growth factors, scaffolding adaptors, cytokines,
and extracellular matrix receptors that possess a SH-2 domain [89,91]. In particular, SHP2 is required for
the activation of the Ras GTPase/extracellular signal-regulated kinase (ERK) signaling cascade [90–92].
The exact mechanism of activation remains unclear; however, it is known that ERK activation results in
the inactivation of the pro-apoptotic proteins Bim (Bcl-2-like protein 11) and BAD (Bcl-2-associated death
promoter), members of the Bcl-2 family of proteins. It also has been implicated in the regulation of the
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway, which results in the promotion of
cell survival through the suppression of caspase 3-mediated apoptosis [93].
Germline gain-of-function mutations of PTPN11 cause ~50% of the cases of the genetic disease
Noonan Syndrome, a disorder that causes abnormal development in different parts of the body
and is associated with the increased risk of malignancy and leukemia [90–92,94]. The rare genetic
disease LEOPARD syndrome, a variant of Noonan Syndrome, given the similarities in characteristic
symptoms, is also caused by germline mutations in PTPN11; however, these missense mutations
inactivate SHP2 [94]. SHP2 has been established as a major oncogenic protein, and in fact, PTPN11
was the first proto-oncogene identified to encode a tyrosine phosphatase [95]. PTPN11 mutations
have been identified in lung, breast, and colon cancer, leukemia, neuroblastoma, and melanoma.
The dysregulation of SHP2 in cancer cells has been implicated to play a role in tumor invasion and
metastasis, apoptosis, cell proliferation, DNA damage repair, and chemoresistance [90,92,96].
Given that SHP2 is primarily known to promote cancer, it seems counter-intuitive that it
would function to dephosphorylate STAT3; however, some studies have revealed that SHP2 shows
some tumor suppressive capabilities through its inactivation of STAT3. Bard-Chapeau et al. [97]
demonstrated that the knockout of SHP2 in hepatocytes of mice caused liver inflammation and
necrosis, leading to nodular regenerative hyperplasia. SHP2-deficient mice also presented an increase
in spontaneous hepatocellular adenomas and chemically-induced HCCs as a result of an increase in
STAT3-mediated inflammatory signaling. In agreement with these findings, SHP2 is downregulated in
a small population of human HCCs [97]. Another study showed that SHP2 expression is also repressed
in human esophageal squamous cell cancer (ESCC), and SHP2 knockdown results in increased ESCC
cell proliferation in vitro and in vivo, which corresponded with a significant increase in phosphorylated
STAT3 [98]. Moreover, Huang et al. [99] demonstrated that SHP2 inhibition of colorectal cancer cell
proliferation and migration corresponded with the negative regulation of STAT3 by SHP2; more
importantly, low expression levels of SHP2 and high expression levels of phosphorylated STAT3 were
associated with poor patient prognosis and vice versa. As mentioned above, SHP2 has been shown to
cooperate with SHP1 and TC-PTP to dephosphorylate STAT3 in response to UV irradiation as part of
an initial protective response against skin carcinogenesis [80]. Additionally, in melanoma cells, the loss
of glucose-phosphate dehydrogenase, a key metabolic enzyme that is highly expressed in different
cancers, and NADPH oxidase 4 inhibit cell proliferation via the suppression of SHP2 and Src, which
regulate STAT3 activation and DNA binding activity, respectively [100].
SHP2 has also been implicated in the regulation of STAT1 and STAT5. STAT1 mediates various
biological functions in normal cells, such as cell death, cell growth inhibition, immune system
stimulation, and cell differentiation regulation [101]. The knockout of SHP2 in mouse fibroblast
cells resulted in enhanced and prolonged STAT1 phosphorylation at both Y701 and S727, induced by
interferon (IFN) γ, and an immunoprecipitation assay confirmed that SHP2 interacts directly with
STAT1 to negatively regulate it [102]. Interestingly, STAT1 is primarily considered to be a tumor
suppressor. Consistent with this hypothesis, Liu et al. found that SHP2 expression is high in human
prostate cancer cell lines, which coincided with low STAT1 phosphorylation and decreased T-cell
activation [103]. Additionally, SHP2 expression is upregulated in human head and neck cancer tissue,
and an in vitro study showed that the loss of SHP2 promoted STAT1 activation, which reduced human
leukocyte antigen class I levels, leading to secretion of inflammatory, T-cell-attracting chemokines [104].
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With regards to STAT5, Chen et al. demonstrated that SHP2—and not SHP1—directly accelerates
the dephosphorylation of STAT5a [105]. It was also demonstrated that a SHP2 deficiency in
human CD34+ hematopoietic progenitor cells significantly inhibited growth factor-mediated cell
survival, proliferation, and differentiation via the downregulation of ERK1/2, AKT, and JAK/STAT5
signaling [83].
7. MEG2/Protein Tyrosine Phosphatase Non-Receptor Type 9
PTP non-receptor type 9, otherwise known as PTP-MEG2 or simply, MEG2, is a cytosolic
non-transmembrane PTP encoded by PTPN9 that is comprised of a PTP domain and a unique
lipid-binding domain near the N-terminus. This domain has sequence similarity with yeast
phosphatidylinositol transfer protein (Sec14p) and cellular retinaldehyde binding protein, and it
targets MEG2 to secretory vesicles through its ability to bind to phosphatidylinositol 3,4,5-triphosphate
(PIP3) and phosphatidylserine [106,107]. MEG2 is widely expressed in different tissues, such as
brain, leukocytes, and endocrine cells [108,109]. However, the functions of PTP-MEG2 have not
been completely characterized yet. Some research has demonstrated that it regulates the growth and
expansion of erythroid cells, and it regulates embryonic development [110,111]. Other studies have
provided useful progress towards identifying a few substrates of MEG2. MEG2 has been shown to
dephosphorylate the nerve growth factor (NGF) receptor TrkA at multiple sites, which resulted in the
inhibition of TrkA signaling and NGF-mediated cell differentiation [107]. Additionally, MEG2 has been
shown to dephosphorylate and deactivate the insulin receptor in hepatocytes, which downregulates
insulin signaling [112]. The use of a substrate-trapping mutant revealed that MEG2 dephosphorylates
vascular endothelial growth factor (VEGF) receptor 2, which corresponded with decreased VEGF
receptor 2 signaling, as evidenced by the reduced expression levels of the downstream molecules
IL-6 and IL-8 [106]. Su et al. [113] were the first to show that STAT3 is yet another substrate of MEG2.
Co-immunoprecipitation and glutathione S-transferase (GST) pull-down assays demonstrated that
MEG2 directly interacts with STAT3 in vitro, and this interaction was confirmed in in vivo mouse
brain tissue and human breast cancer cells. Furthermore, MEG2 dephosphorylated STAT3 at Y705
in a time- and dose-dependent manner, and the inactivation of STAT3 resulted in decreased breast
tumor growth [113]. Jin et al. further revealed that the STAT3 inhibitor methyllucidone, a natural
compound derived from the fruits of Lindera erythrocarpa Makino, inhibited STAT3 activation by
upregulating MEG2 expression and, thereby, was effective at inhibiting prostate cancer cell survival
and proliferation [114].
8. T-Cell Protein Tyrosine Phosphatase
TC-PTP (encoded by PTPN2) is a non-transmembrane protein belonging to the non-receptor,
tyrosine-specific subfamily of PTPs, which also includes PTP1B. TC-PTP is comprised of a conserved
catalytic domain that shares a high degree (>72%) of sequence and structural homology with the
catalytic domain of PTP-1B and a non-catalytic C-terminal domain. TC-PTP has two splice variants that
express two isoenzymes: TC45 (45 kDa) possesses a shorter hydrophilic C-terminal domain containing
a NLS and TC48 (48 kDa), which has a hydrophobic endoplasmic reticulum targeting sequence within
its C-terminal domain [115,116]. TC45 is the major form of TC-PTP in most species; it is primarily found
in the nucleus of most cell types, and shuttles between the nucleus and cytoplasm in response to growth
factor and cytokine receptor signaling to dephosphorylate distinct substrates [116–118]. Although it is
most highly expressed in hematopoietic cells, TC-PTP is ubiquitously expressed in most embryonic
and adult tissues [119]. Similar to other PTPs, it regulates major cell processes, such as cell growth
and differentiation. For example, insulin, the hormone that maintains glucose homeostasis, triggers
the accumulation of TC-PTP in the cytoplasm where it can dephosphorylate the insulin receptor,
resulting in the downregulation of insulin signaling [120]. Moreover, TC-PTP has been shown to play
unique roles in the immune system [121]. TC-PTP-deficient (Ptpn2−/− ) mice develop thymus atrophy
and succumb to anemia and progressive systemic inflammatory disease within the first 2 weeks of
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birth [122]. Additionally, an increase in pro-inflammatory cytokines, such as IFN-γ, IFN-α, or TNF-α,
could be found in the 3 days after birth [123]. Older T-cell-specific TC-PTP-deficient (Ptpn2−/− ) mice
suffer from spontaneous autoimmunity corresponding with enhanced activation of both CD4 and CD8
T cells in vivo, leading to a reduction in the T-cell receptor (TCR) threshold of activation. In addition, a
recent report demonstrated that TC-PTP is a negative regulator of interleukin-7 receptor (IL-7R)-STAT
signaling in T-cell progenitors and works as a critical safeguard for efficient T-cell differentiation [124].
TC-PTP has several substrates such as EGF receptor, JAK, and STAT [125,126]. As previously
mentioned, TC-PTP is able to play a regulatory role in insulin signaling. TC-PTP-deficient mice
(Ptpn2+/− ) displayed decreased gluconeogenesis as a result of the upregulation of STAT3 signaling
and insulin-stimulated AKT signaling in the liver [127]. Also, it has been revealed that TC-PTP has
some tumor suppressor capabilities. TC-PTP is deleted in a small proportion of human T-cell acute
lymphoblastic leukemia, leading to increased JAK/STAT signaling [128,129]. Another study reported
a loss of TC-PTP in triple-negative primary breast cancer, and TC-PTP deficiency in human breast
cancer cell lines resulted in increased cell proliferation in vitro and xenograft in vivo via reduced
SFK (Src family protein tyrosine kinases) and STAT3 signaling [130]. Studies have shown that
STAT3 plays a critical role in the development of either chemically or UVB-induced skin cancer
by promoting the survival and proliferation of keratinocytes during carcinogenesis [131–137]. Our
research group has reported extensively on the role of TC-PTP in the regulation of STAT3 signaling
in skin carcinogenesis. Our studies have demonstrated that UVB radiation induces TC-PTP nuclear
translocation in mouse keratinocytes, which resulted in a significant decrease in cell proliferation
corresponding with a decrease in STAT3 phosphorylation [138,139], suggesting that TC-PTP may
serve as a tumor suppressor against UVB-mediated skin carcinogenesis. As previously mentioned,
TC-PTP is primarily found in the cell nucleus due to a NLS in the C-terminus. However, we
revealed that UVB irradiation triggers phosphorylation at the T179 residue of TC-PTP by AKT,
which is required for the nuclear translocation of TC-PTP via 14-3-3σ, a protein critical to signal
transduction and cell cycle regulation [139,140]. TC-PTP was also implicated in chemically induced skin
carcinogenesis. TC-PTP knockout in mouse epidermis (K14Cre.Ptpn2fl/fl ) led to reduced susceptibility
to tumor initiator 7,12-dimethylbenz[a]anthracene (DMBA)-induced apoptosis. Furthermore, TC-PTP
deficiency significantly increased epidermal thickness and hyperproliferation following treatment with
12-O-tetradecanoylphorbol-13-acetate (TPA), a tumor promoter. During two-stage skin carcinogenesis,
the loss of TC-PTP promoted TPA-induced skin carcinogenesis via the upregulation of STAT3 and
AKT signaling, whereas the inhibition of STAT3 or AKT recovered the effects of TC-PTP as a tumor
suppressor in TC-PTP deficient cell lines (Figure 2) [141]. Our findings implied that TC-PTP is a
potential novel target for the prevention of skin cancer through its role in the regulation of STAT3 and
AKT signaling.
TC-PTP is the only PTP known to regulate STAT1 other than SHP2. The interaction between
STAT1 and TC-PTP may involve associated proteins, such as β-arrestin 1. For instance, during IFN-γ
signaling, β-arrestin 1, acting as a scaffold, directly interacts with STAT1 and promotes STAT1 tyrosine
dephosphorylation by recruiting TC45 [142]. However, more recent evidence has suggested that
β-arrestin 1 does not inhibit STAT1 transcriptional activity nor does it prevent the activation of IFN-γ
target genes. Thus, β-arrestin 1 has not been confirmed as a STAT1-interacting protein, and in fact, it
has been shown to be negatively regulated in STAT1 signaling [143]. Another interesting study has
reported that nuclear TC45 is a major PTP regulator of nuclear STAT1 [144]. It was demonstrated that
STAT1 was hyperphosphorylated and activated in TC-PTP-deficient cells. The dephosphorylation
of pSTAT1 in TC-PTP deficient mouse fibroblasts was strongly delayed, resulting in the expression
of STAT1 target genes. Bussieres-Marmen et al. demonstrated that the knockout of TC-PTP in the
intestinal epithelial cells in mice resulted in severe colitis corresponding with increased inflammation
and increased cell proliferation via the activation of STAT1 [145]. Interestingly, genetic variations
in PTPN2 have been associated with the chronic inflammatory bowel disease known as Crohn’s
disease [146].
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9. Conclusions
The STAT family of transcription factors are vital to the proper functioning of most cell types.
They transduce the signals required for the activation of several key cellular processes. A STAT is
activated primarily by tyrosine phosphorylation of its C-terminal tail. Tyrosine phosphorylation is a
reversible post-translational modification that regulates proteins in multiple ways; however, during
carcinogenesis, the rate and duration of tyrosine phosphorylation can become disrupted by genetic
mutation or by the inactivation of important phosphotyrosine regulators. STAT3 is constitutively
activated in many cancers; therefore, the mechanisms that regulate STAT3 have been, and continue to
be, heavily investigated in order to identify newer and more effective targets for anti-cancer therapies.
PTPs are the primary enzymes to dephosphorylate phosphotyrosine proteins. The current research
has greatly increased our understanding of how STAT3 is regulated by PTP. To date, seven PTPs have
been implicated in the regulation of STAT3: PTPRD, PTPRT, PTPRK, SHP1, SHP2, MEG2, and TC-PTP
(Figure 3). However, there are 107 members of the PTP family, many with unknown functions. More
research is still needed to unravel the many mechanisms by which PTP regulation may contribute to
human disease in order to improve upon our current clinical therapies.
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